The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

By sjmartinez • June 4, 2025

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO Open. 2025 Jun 2;10(6):105294. doi: 10.1016/j.esmoop.2025.105294. Epub ahead of print. PMID: 40460679.

Tags: Antibody–drug conjugate, body mass index, Hematology/Oncology, metastatic triple-negative breast cancer, Obesity, Publications, Sacituzumab govitecan

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]